Johannes‐Peter Stasch

Author

Bayer (Germany)

Also Known As

Damian Brockschnieder, J.-P. Stasch, Johannes-Peter Stasch, Johannes‐Peter Stasch, Stasch, Johannes-Peter

232

Publications

8.6K

Citations

H-Index

105

Concepts

All Affiliations

Bayer (Germany)Martin Luther University Halle-Wittenberg Medizinische Hochschule Hannover Bayer (United States)Witten/Herdecke University

About

Johannes‐Peter Stasch is an author at Bayer (Germany) specializing in medicine, pharmacology, and physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	39	2.8K
2	Natural Sciences	11	13	1.5K
3	Public Health	6	6	545
4	Health Sciences	3	3	70
5	Engineering	1	1	44

Johannes‐Peter Stasch

Publications

Citations

H-Index

Page 1

	Year	Citations
Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels Johannes‐Peter Stasch, Péter Schmidt, Pavel I. Nedvetsky, Journal of Clinical Investigation	2006	443
The Concise Guide to PHARMACOLOGY 2023/24: Enzymes S P H Alexander, Doriano Fabbro, Eamonn Kelly, British Journal of Pharmacology Drug TargetSystem PharmacologyPre-clinical PharmacologySystems PharmacologyMolecular Pharmacology	2023	423
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Enzymes S P H Alexander, Doriano Fabbro, Eamonn Kelly, British Journal of Pharmacology Drug TargetCellular PharmacologySystem PharmacologyChemical BiologyPre-clinical Pharmacology	2021	380
NO‐ and haem‐independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle Johannes‐Peter Stasch, Péter Schmidt, Cristina Alonso‐Alija, British Journal of Pharmacology Haem‐independent ActivationCardiovascular PharmacologyPharmacotherapyChemical BiologyMolecular Pharmacology	2002	308
Effect of YC‐1, an NO‐independent, superoxide‐sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators Alexander Mülsch, Johann Bauersachs, Andreas Schäfer, British Journal of Pharmacology	1997	224
Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular Remodeling Rio Dumitrascu, Hossein Ardeschir Ghofrani, Eva Dony, Circulation	2006	219
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure Markus Follmann, Jens Ackerstaff, Gorden Redlich, Journal of Medicinal Chemistry Medicinal ChemistryHeart FailureChronic Heart FailureCardiomyopathyCardiovascular Disease	2017	189
Discovery of Riociguat (BAY 63‐2521): A Potent, Oral Stimulator of Soluble Guanylate Cyclase for the Treatment of Pulmonary Hypertension Joachim Mittendorf, Stefan Weigand, Cristina Alonso‐Alija, ChemMedChem Molecular PharmacologyPulmonary Arterial HypertensionBiochemistryMedicineDrug Discovery	2009	180
The Concise Guide to PHARMACOLOGY 2023/24: Catalytic receptors S P H Alexander, Doriano Fabbro, Eamonn Kelly, British Journal of Pharmacology	2023	150
Effects of In Vivo Nitroglycerin Treatment on Activity and Expression of the Guanylyl Cyclase and cGMP-Dependent Protein Kinase and Their Downstream Target Vasodilator-Stimulated Phosphoprotein in Aorta Alexander Mülsch, Matthias Oelze, Stefan Klöss, Circulation	2001	133

Page 1